Cowden syndrome and the PTEN hamartoma tumor syndrome: Systematic review and revised diagnostic criteria

Journal of the National Cancer Institute

Volumn 105, Issue 21, 2013, Pages 1607-1616

  Pilarski, Robert ^a,b   Burt, Randall ^c,d   Kohlman, Wendy ^c,d   Pho, Lana ^c,d   Shannon, Kristen M ^e   Swisher, Elizabeth ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ACANTHOSIS; AUTISM; BRAIN DAMAGE; BREAST DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLON CANCER; COLON POLYP; CONGENITAL BLOOD VESSEL MALFORMATION; COWDEN SYNDROME; EVIDENCE BASED PRACTICE; GENE MUTATION; GOITER; HAMARTOMA; HASHIMOTO DISEASE; HUMAN; KIDNEY CARCINOMA; LIPOMATOSIS; MEDICAL LITERATURE; PENIS DISEASE; PRIORITY JOURNAL; REVIEW; SKIN DEFECT; SYSTEMATIC REVIEW; TESTIS TUMOR; THYROID ADENOMA; THYROID NODULE; UROGENITAL TRACT MALFORMATION; UTERUS MYOMA;

BRAIN; BRAIN NEOPLASMS; BREAST; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; PTEN PHOSPHOHYDROLASE; SKIN; SKIN NEOPLASMS; THYROID GLAND; THYROID NEOPLASMS; UROGENITAL NEOPLASMS; UROGENITAL SYSTEM;

EID: 84890465438     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt277     Document Type: Review

References (121)

1. Lloyd KM, Denis M. Cowden's disease: A possible new symptom complex with multiple system involvement. Ann Intern Med. 1963;58(1):136-142.
2. Weary PE, Gorlin RJ, Gentry WC Jr, Comer JE, Greer KE. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol. 1972;106(5):682-690.
3. Nelen MR, van Staveren CG, Peeters EAJ, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet. 1997;6(8):1383-1387.
4. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64-67.
5. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet. 1992;44(3):307-314.
6. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8(8):1461-1472.
7. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: An evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet. 2011;48(8):505-512.
8. Hendriks YM, Verhallen JT, van der Smagt JJ, et al. Bannayan-Riley- Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. Fam Cancer. 2003;2(2):79-85.
9. Salem OS, Steck WD. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J Am Acad Dermatol. 1983;8(5):686-696.
10. Nelen MR, Padberg GW, Peeters EAJ, et al. Localization of the gene for Cowden disease to 10q22-23. Nat Genet. 1996;13(1):114-116.
11. Starink TM, van der Veen JPW, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet. 1986;29(3):222-233.
12. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 2000;37(11):828-830.
13. Zbuk KM, Stein, J.L. & Eng, C. PTEN Hamartoma Tumor Syndrome (PHTS). GeneReviews at GeneTests: Medical Genetics Information Resource. http://www.genetests.org. Accessed September 12, 2013.
14. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotypephenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507-515.
15. Nelen MR, Kremer H, Konings IBM, et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267-273.
16. Tsou HC, Teng DH, Ping XL, et al. The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet. 1997;61(5):1036-1043.
17. Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet. 2011;88(1):42-56.
18. National Comprehensive Cancer Network I. The NCCN Guidelines Genetic/Familial High-Risk Assessment: Breast and Ovarian. http://www.nccn.org. Accessed September 12, 2013.
19. Lok C, Viseux V, Avril MF, et al. Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore). 2005;84(2):129-136.
20. Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet. 2007;44(9):594-602.
21. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8(1):6.
22. Zhou XP, Marsh DJ, Morrison CD, et al. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet. 2003;73(5):1191-1198.
23. Robinson S, Cohen AR. Cowden disease and Lhermitte-Duclos disease: An update. Case report and review of the literature. Neurosurg Focus. 2006;20(1):E6.
24. Hanssen AM, Fryns JP. Cowden syndrome. J Med Genet. 1995; 32(2):117-119.
25. Parisi M, Dinulos MB, Leppid KA, Sybert VP, Eng C, Hudgins L. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet. 2001;38(1):52-57.
26. Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007;44(9):579-585.
27. Mester JL, Tilot AK, Rybicki LA, Frazier TW 2nd, Eng C. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet. 2011;19(7):763-768.
28. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet. 2005;42(4):318-321.
29. Herman GE, Butter E, Enrile B, Pastore M, Prior TW, Sommer A. Increasing knowledge of PTEN germline mutations: two additional patients with autism and macrocephaly. Am J Med Genet A. 2007;143(6):589-593.
30. Buxbaum JD, Cai G, Chaste P, et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):484-491.
31. McBride KL, Varga EA, Pastore MT, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res. 2010;3(3):137-41.
32. Varga EA, Pastore M, Prior T, Herman GE, McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med. 2009;11(2):111-117.
33. Conti S, Condo M, Posar A, et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. J Child Neurol. 2012;27(3):392-397.
34. Brownstein MH, Wolf M, Bikowski JB. Cowden's disease: A cutaneous marker of breast cancer. Cancer. 1978;41(6):2393-2398.
35. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: A clinical and genetic study in 21 patients. Clin Genet. 1986;29(3):222-233.
36. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255-263.
37. Riegert-Johnson DL, Gleeson FC, Roberts M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8(1):6.
38. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res.18(2):400-407.
39. Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38(3):159-164.
40. Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotypephenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet. 1998;7(3):507-515.
41. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: An evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet.48(8):505-512.
42. Pilarski R. Cowden syndrome: A critical review of the clinical literature. J Genet Couns. 2009;18(1):13-27.
43. Miltenburg DM, Speights VO Jr. Benign breast disease. Obstet Gynecol Clin North Am. 2008;35(2):285-300, ix.
44. Norwood SL. Fibrocystic breast disease. An update and review. J Obstet Gynecol Neonatal Nurs. 1990;19(2):116-121.
45. Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med. 1998;13(9):640-645.
46. Starink TM. Cowden's disease: Analysis of fourteen new cases. J Am Acad Dermatol. 1984;11(6):1127-1141.
47. Cilotti A, Bagnolesi P, Napoli V, Lencioni R, Bartolozzi C. [Solitary intraductal papilloma of the breast. An echographic study of 12 cases]. Radiol Med. 1991;82(5):617-20.
48. Renshaw AA, Derhagopian RP, Tizol-Blanco DM, Gould EW. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol. 2004;122(2):217-221.
49. Ahmadiyeh N, Stoleru MA, Raza S, Lester SC, Golshan M. Management of intraductal papillomas of the breast: An analysis of 129 cases and their outcome. Ann Surg Oncol. 2009;16(8):2264-2269.
50. Agoff SN, Lawton TJ. Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? Am J Clin Pathol. 2004;122(3):440-443.
51. Sydnor MK, Wilson JD, Hijaz TA, Massey HD, Shaw de Paredes ES. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007;242(1):58-62.
52. Sohn V, Keylock J, Arthurs Z, et al. Breast papillomas in the era of percutaneous needle biopsy. Ann Surg Oncol. 2007;14(10):2979-2984.
53. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927-1933.
54. Stanich PP, Owens VL, Sweetser S, et al. Colonic polyposis and neoplasia in Cowden syndrome. Mayo Clinic Proc. 2011;86(6):489-492.
55. Levi Z, Baris HN, Kedar I, et al. Upper and lower gastrointestinal findings in PTEN mutation-positive cowden syndrome patients participating in an active surveillance program. Clin Transl Gastroenterol. 2011;2(11):e5.
56. Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: A clinical and molecular review. Am J Gastroenterol. 2005;100(2):476-490.
57. Kato M, Mizuki A, Hayashi T, et al. Cowden's disease diagnosed through mucocutaneous lesions and gastrointestinal polyposis with recurrent hematochezia, unrevealed by initial diagnosis. Int Med. 2000;39(7): 559-563.
58. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-407.
59. McGarrity TJ, Wagner Baker MJ, et al. GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations. Am J Gastroenterol. 2003;98(6):1429-1434.
60. Kay PS, Soetikno RM, Mindelzun R, Young HS. Diffuse esophageal glycogenic acanthosis: An endoscopic marker of Cowden's disease. Am J Gastroenterol. 1997;92(6):1038-1040.
61. Al-Thihli K, Palma L, Marcus V, et al. A case of Cowden's syndrome presenting with gastric carcinomas and gastrointestinal polyposis. Nat Clin Pract Gastroenterol Hepatol. 2009;6(3):184-189.
62. Black D, Bogomolniy F, Robson ME, Offit K, Barakat RR, Boyd J. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol. 2005;96(1):21-24.
63. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.
64. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90(6):967-973.
65. Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N, Coomarasamy A. The prevalence of congenital uterine anomalies in unselected and high-risk populations: A systematic review. Hum Reprod Update. 2011;17(6):761-771.
66. Paulozzi LJ, Erickson JD, Jackson RJ. Hypospadias trends in two US surveillance systems. Pediatrics. 1997;100(5):831-834.
67. Caiulo VA, Caiulo S, Gargasole C, et al. Ultrasound mass screening for congenital anomalies of the kidney and urinary tract. Pediatr Nephrol. 2012;27(6):949-953.
68. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am J Clin Pathol. 1992;97(5):705-712.
69. Lynch ED, Ostermeyer EA, Lee MK, et al. Inherited mutations in PTEN that are associated with breast cancer, Cowden syndrome and juvenile polyposis. Am J Hum Genet. 1997;61(6):1254-1260.
70. Carlson HE, Burns TW, Davenport SL, et al. Cowden disease: gene marker studies and measurements of epidermal growth factor. Am J Hum Genet. 1986;38(6):908-917.
71. Brownstein MH, Mehregan AH, Bilowski JB. Trichilemmomas in Cowden's disease. JAMA. 1977;238(1):26.
72. Starink TM, Hausman R. The cutaneous pathology of facial lesions in Cowden's disease. J Cutan Pathol. 1984;11(5):331-337.
73. Starink TM, Meijer CJ, Brownstein MH. The cutaneous pathology of Cowden's disease: new findings. J Cutan Pathol. 1985;12(2):83-93.
74. Masmoudi A, Chermi ZM, Marrekchi S, et al. Cowden syndrome. J Dermatol Case Rep. 2011;5(1):8-13.
75. Porter S, Cawson R, Scully C, Eveson J. Multiple hamartoma syndrome presenting with oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;82(3):295-301.
76. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64-67.
77. Brownstein MH, Mehregan AH, Bikowski JB, Lupulescu A, Patterson JC. The dermatopathology of Cowden's syndrome. Br J Dermatol. 1979;100(6):667-673.
78. Fargnoli MC, Orlow SJ, Semel-Concepcion J, Bolognia JL. Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome. Arch Dermatol. 1996;132(10):1214-1218.
79. Capitan Canadas LM, Salinas Sanchez JL, Martinez Castillo SL, et al. Multiple oral fibropapillomatosis as an initial manifestation of Cowden syndrome. Case report. Med Oral Patol Oral Cir Bucal. 2006;11(4):E319-E324.
80. Oh JG, Yoon CH, Lee CW. Case of Cowden syndrome associated with eccrine angiomatous hamartoma. J Dermatol. 2007;34(2):135-137.
81. van der Velden JJ, Vreeburg M, Smeets EE, Schrander-Stumpel CT, van Steensel MA. Skin abnormalities in individuals with macrocephaly: Cowden disease from a dermatologist's point of view. Int J Dermatol. 2008;47(Suppl 1):45-48.
82. Vasovcak P, Krepelova A, Puchmajerova A, et al. A novel mutation of PTEN gene in a patient with Cowden syndrome with excessive papillomatosis of the lips, discrete cutaneous lesions, and gastrointestinal polyposis. Eur J Gastroenterol Hepatol. 2007;19(6):513-517.
83. Ferran M, Bussaglia E, Lazaro C, Matias-Guiu X, Pujol RM. Acral papular neuromatosis: An early manifestation of Cowden syndrome. Br J Dermatol. 2008;158(1):174-176.
84. Perez-Nunez A, Lagares A, Benitez J, et al. Lhermitte-Duclos disease and Cowden disease: clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review. Acta Neurochir (Wien). ;146(7):679-690.
85. Schaffer JV, Kamino H, Witkiewicz A, McNiff JM, Orlow SJ. Mucocutaneous neuromas: An underrecognized manifestation of PTEN hamartoma-Tumor syndrome. Arch Dermatol. 2006;142(5):625-632.
86. Turnbull MM, Humeniuk V, Stein B, Suthers GK. Arteriovenous malformations in Cowden syndrome. J Med Genet. 2005;42(8):e50.
87. Jarrett R, Walker L, Soilleux E, Bowling J. Dermoscopy of Cowden syndrome. Arch Dermatol. 2009;145(4):508-509.
88. Barnhill RL, Albert LS, Shama SK, Goldenhersh MA, Rhodes AR, Sober AJ. Genital lentiginosis: A clinical and histopathologic study. J Am Acad Dermatol. 1990;22(3):453-460.
89. Bannayan GA. Lipomatosis, angiomatosis, and macrencephalia: A previously undescribed congenital syndrome. Arch Pathol. 1971;92(1):1-5.
90. Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet. 1999;8(8):1461-1472.
91. Nuss DD, Aeling JL, Clemons DE, Weber WN. Multiple hamartoma syndrome (Cowden's disease). Arch Dermatol. 1978;114(5):743-746.
92. Okunaga T, Takahata H, Nakamura M, Iwasaki K. [A case report of Lhermitte-Duclos disease with systematic AVMs]. No To Shinkei. 2003;55(3):251-255.
93. Takaya N, Iwase T, Maehara A, Nishiyama S, Nakanishi S, Yamana D, et al. Transcatheter embolization of arteriovenous malformations in Cowden disease. Jpn Circ J. 1999;63(4):326-329.
94. Rustad CF, Bjornslett M, Heimdal KR, Maehle L, Apold J, Moller P. Germline PTEN mutations are rare and highly penetrant. Hered Cancer Clin Pract. 2006;4(4):177-185.
95. Buisson P, Leclair MD, Jacquemont S, et al. Cutaneous lipoma in children: 5 cases with Bannayan-Riley-Ruvalcaba syndrome. J Pediatr Surg. 2006;41(9):1601-1603.
96. Chan OT, Haghighi P. Hamartomatous polyps of the colon: ganglioneuromatous, stromal, and lipomatous. Arch Pathol Lab Med. 2006;130(10):1561-1566.
97. Al-Daraji WI, Ramsay HM, Ali RB. Storiform collagenoma as a clue for Cowden disease or PTEN hamartoma tumour syndrome. J Clin Pathol. 2007;60(7):840-842.
98. Rapini RP, Golitz LE. Sclerotic fibromas of the skin. J Am Acad Dermatol. 1989;20(2 Pt 1):266-71.
99. Trufant JW, Greene L, Cook DL, McKinnon W, Greenblatt M, Bosenberg MW. Colonic ganglioneuromatous polyposis and metastatic adenocarcinoma in the setting of Cowden syndrome: A case report and literature review. Hum Pathol. 2012;43(4):601-604.
100. Greene SL, Thomas JR 3rd, Doyle JA. Cowden's disease with associated malignant melanoma. Int J Dermatol. 1984;23(7):466-467.
101. Longy M, Lacombe D. Cowden disease. Report of a family and review. Annales de Génetique. 1996;39(1):35-42.
102. Reifenberger J, Rauch L, Beckmann MW, Megahed M, Ruzicka T, Reifenberger G. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol. 2003;148(5):1040-1046.
103. Lindsay C, Boardman L, Farrell M. Testicular hamartomas in Cowden disease. J Clin Ultrasound. 2003;31(9):481-483.
104. Woodhouse JB, Delahunt B, English SF, Fraser HH, Ferguson MM. Testicular lipomatosis in Cowden's syndrome. Mod Pathol. 2005;18(9):1151-1156.
105. Woodhouse J, Ferguson MM. Multiple hyperechoic testicular lesions are a common finding on ultrasound in Cowden disease and represent lipomatosis of the testis. Br J Radiol. 2006;79(946):801-803.
106. Walker RN, Murphy TJ, Wilkerson ML. Testicular hamartomas in a patient with Bannayan-Riley-Ruvalcaba syndrome. J Ultrasound Med. 2008;27(8):1245-1248.
107. Rasalkar DD, Paunipagar BK. Testicular hamartomas and epididymal tumor in a cowden disease: A case report. Case Rep Med. 2010;2010:135029.
108. Harper M, Arya M, Peters JL, Buckingham S, Freeman A, O'Donoghue EP. Intratesticular lipoma. Scand J Urol Nephrol 2002;36(3):223-224.
109. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endicrinol Metab. 2008;22(6):901-911.
110. Luo J, McManus C, Chen H, Sippel RS. Are there predictors of malignancy in patients with multinodular goiter? J Surg Res. 2012;174(2):207-210.
111. Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: A century later. Adv Anat Pathol. 2012;19(3):181-186.
112. Laury AR, Bongiovanni M, Tille JC, Kozakewich H, Nose V. Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity. Thyroid. 2011;21(2):135-144.
113. Milas M, Mester J, Metzger R, et al. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery. 2012;152(6):1201-1210.
114. Smith JR, Marqusee E, Webb S, et al. Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinol Metab. 2011;96(1):34-37.
115. Howlader NNA, Krapcho M, Neyman N, et al., eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed September 13, 2013.
116. Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab. 2011;96(12):E2063-E2071.
117. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer. 1985;56(3):531-538.
118. Pakdaman MN, Rochon L, Gologan O, et al. Incidence and histopathological behavior of papillary microcarcinomas: study of 429 cases. Otolaryngol Head Neck Surg. 2008;139(5):718-722.
119. Nagy R, Ganapathi S, Comeras I, et al. Frequency of germline PTEN mutations in differentiated thyroid cancer. Thyroid. 2011; 21(5):505-510.
120. Pal T, Hamel N, Vesprini D, et al. Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. Fam Cancer. 2001;1(1):17-24.
121. Daniels MS, Rich T, Weissman S, Pilarski R. Lifetime cancer risks of PTEN mutation carriers -letter. Clin Cancer Res. 2012;18(15):4213; author reply 4214.